Xin Lang Cai Jing·2025-09-09 02:15Group 1 - The core viewpoint of the news is that BeiGene's stock has seen a significant increase, with a rise of 5.03% to 334.00 CNY per share, and a total market capitalization of 514.31 billion CNY [1] - BeiGene, founded on October 28, 2010, and listed on December 15, 2021, is primarily engaged in the research, development, production, and commercialization of innovative drugs, with 99.19% of its revenue coming from oncology drugs [1] - The trading volume for BeiGene reached 1.322 billion CNY, with a turnover rate of 3.46% [1] Group 2 - From the perspective of fund holdings, one fund under Guotai Haitong Asset Management has a significant position in BeiGene, specifically the Guotai Junan Innovative Medicine Mixed Fund A, which reduced its holdings by 5,600 shares in the second quarter [2] - The fund currently holds 34,500 shares, representing 5.35% of its net asset value, ranking it as the sixth-largest holding [2] - The fund has achieved a year-to-date return of 32.77% and a one-year return of 42.78%, with a total fund size of 1.07 billion CNY [2]